Ceralasertib is under clinical development by AstraZeneca and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Ceralasertib’s likelihood of approval (LoA) and phase transition for Triple-Negative Breast Cancer (TNBC) took place on 18 Jul 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ceralasertib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Ceralasertib overview

Ceralasertib is under development for the treatment of head and neck cancer squamous cell carcinoma, metastatic triple negative breast cancer, HER-2 negative breast cancer, non-small cell lung cancer, metastatic melanoma, advanced biliary tract cancer, endometrial cancer, cervical cancer, uterine cancer, small cell lung cancer, chronic myelomonocytic leukemia, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, metastatic colorectal cancer, salivary gland cancer, myelodysplastic syndrome, homologous-recombination deficient (HRD) of adenocarcinoma of the gastroesophageal junction, non-hodgkin's lymphoma, ovarian cancer, peritoneal cancer, fallopian tube cancer, refractory solid tumors including lung adenocarcinoma, metastatic renal cell carcinoma, urothelial cell carcinoma, pancreatic ductal adenocarcinoma, other solid tumors. The drug candidate is administered through oral route in the form of film coated tablet and gelatin coated capsule. It targets ataxia telangiectasia and rad3 related (ATR) kinase.

It was also under development for the treatment of prolymphocytic leukemia (PLL), Burkitt lymphoma, acute lymphocytic leukemia, hairy cell leukemia (HCL), relapsed/refractory chronic lymphocytic leukemia (CLL), indolent  b-cell lymphoma and B cell lymphomas.

AstraZeneca overview

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

Quick View Ceralasertib LOA Data

Report Segments
  • Innovator
Drug Name
  • Ceralasertib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.